Diagnosis of endocrine disease: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper

European Journal of Endocrinology

Volumn 171, Issue 2, 2014, Pages

  Giovanella, Luca ^a   Clark, Penelope M ^b   Chiovato, Luca ^c   Duntas, Leonidas ^d   Elisei, Rossella ^e   Feldt Rasmussen, Ulla ^f   Leenhardt, Laurence ^g   Luster, Markus ^h   Schalin Jan̈tti, Camilla ⁱ   Schott, Matthias ^j   Seregni, Ettore ^k   Rimmele, Herald ^l   Smit, Jan ^m   Verburg, Frederik A ⁿ  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY HOSPITAL MARBURG   (Germany)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^k NATIONAL CANCER INSTITUTE   (Italy)

^l Self Help Organization of Thyroid Cancer Patients 'Ohne Schilddrüse Leben E V '   (Germany)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ABLATION THERAPY; ANTIBODY BLOOD LEVEL; AUTOIMMUNE THYROIDITIS; CONGENITAL HYPOTHYROIDISM; DISEASE FREE INTERVAL; ENDOCRINE FUNCTION TEST; FOLLOW UP; HEMITHYROIDECTOMY; HUMAN; IMMUNOASSAY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NON AUTOIMMUNE THYROIDITIS; PATIENT CARE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; THYROTOXICOSIS; THYROTOXICOSIS FACTITIA; TREATMENT INDICATION; ADENOCARCINOMA; BLOOD; CARCINOMA; CONSENSUS DEVELOPMENT; ECHOGRAPHY; NECK; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA; HUMANS; IODINE RADIOISOTOPES; NECK; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 84905252529     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0148     Document Type: Review

References (71)

1. Schlumberger M. Medical progress: papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306. (doi:10.1056/NEJM199801293380506)
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W & European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803. (doi:10.1530/eje.1.02158)
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
4. Reiners C, Hanscheid H, Luster M, Lassmann M & Verburg FA. Radioiodine for remnant ablation and therapy of metastatic disease. Nature Reviews Endocrinology 2011 7 589-595. (doi:10.1038/nrendo.2011.134)
5. Diessl S, Holzberger B, Mäder U, Grelle I, Smit JW, Buck AK, Reiners C & Verburg FA. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clinical Endocrinology 2012 76 586-592. (doi:10.1111/j.1365-2265.2011.04272.x)
6. Verburg FA, Mader U, Tanase K, Thies ED, Diessl S, Buck AK, Luster M & Reiners C. Life expectancy is reduced in differentiated thyroid cancer patients ≥45 years old with extensive local tumour invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. Journal of Clinical Endocrinology and Metabolism 2013 98 172-180. (doi:10.1210/jc.2012-2458)
7. Pacini F. Follow-up of differentiate thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 2002 29 (Suppl 2) 492-496. (doi:10.1007/s00259-002-0847-9)
8. Grebe SKG. Diagnosis and management of thyroid carcinoma: focus on serum thyroglobulin. Expert Review of Endocrinology & Metabolism 2009 4 25-43. (doi:10.1586/17446651.4.1.25)
9. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clinical Chemistry and Laboratory Medicine 2008 46 1067-1073.
10. Haugen BR, Ridgway EC, McLaughlin BA & McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002 12 37-43. (doi:10.1089/105072502753451959)
11. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid carcinoma without diagnostic (131)I scanning. Journal of Clinical Endocrinology and Metabolism 2000 87 1486-1489. (doi:10.1210/jcem.87.4.8445)
12. Wunderlich G, Zöphel K, Crook L, Smith S, Smith BR & Franke WG. A high-sensitivity enzyme-linked immunosorbent assay for serum thyroglobulin. Thyroid 2001 11 819-824. (doi:10.1089/105072501316973064)
13. Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P & Zucchelli GC. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. Journal of Endocrinology 2004 182 287-294. (doi:10.1677/joe.0.1820287)
14. Zöphel K, Wunderlich G & Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003 13 861-865. (doi:10.1089/105072503322401050)
15. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 2007 92 2487-2495. (doi:10.1210/jc.2006-0723)
16. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, Colato C & Zucchelli GC. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clinical Endocrinology 2007 67 434-441. (doi:10.1111/j.1365-2265.2007.02907.x)
17. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S & Fatourechi V. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 2007 92 82-87. (doi:10.1210/jc.2006-0993)
18. U.S. Preventive Services Task Force Ratings: grade definitions. Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003. Rockville: Agency for Healthcare Research and Quality, 2003. (http://www.uspreventiveservicestaskforce.org/3rduspstf/ratings.htm; accessed 30.04.2014)
19. Spencer CA, Takeuchi M & Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clinical Chemistry 1996 42 164-173. (Pubitemid 26030404)
20. Clark PM. Laboratory services for thyroglobulin and implications for monitoring of differentiated thyroid cancer. Journal of Clinical Pathology 2009 62 402-406. (doi:10.1136/jcp.2008.058024)
21. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J et al. Laboratory support for the diagnosis and monitoring of thyroid diseases. Thyroid 2003 13 3-126. (doi:10.1089/105072503321086962)
22. Panteghini M. Assay-related issues in the measurement of cardiac troponins. Clinica Chimica Acta 2009 402 88-93. (doi:10.1016/j.cca.2008.12.037)
23. Clinical and Laboratory Standards Institute. Protocols for Determination of Limits of Detection and Limits of Quantification; Approved Guideline. NCCLS document EP17-A [ISBN 1-56238-551-8], Wayne, PA USA: CLSI; CLSI document EP17, 2004.
24. Armbruster DA & Pry T. Limit of blank, limit of detection and limit of quantitation. Clinical Biochemist Reviews 2008 29 (Suppl 1) S49-S52.
25. Spencer CA & Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nature Clinical Practice Endocrinology & Metabolism 2008 4 223-233. (doi:10.1038/ ncpendmet0757)
26. Feldt-Rasmussen U & Schlumberger M. European inter-laboratory comparison of serum thyroglobulin measurement. Journal of Endocrinological Investigation 1988 11 175-181. (doi:10.1007/BF03350129)
27. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, Carayon P, Ericsson UB, Koutras DA, Lamas de Leon L et al. Human thyroglobulin reference material (CRM 457). 1st Part: assessment of homogeneity, stability and immunoreactivity. Annales de Biologie Clinique 1996 54 337-342. (Pubitemid 27060140)
28. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, Carayon P, Ericsson UB, Koutras DA, Lamas de Leon L et al. Human thyroglobulin reference material (CRM 457). 2nd Part: physicochemical characterization and certification. Annales de Biologie Clinique 1996 54 343-348. (Pubitemid 27060141)
29. Clark P & Franklyn J. Can we interpret serum thyroglobulin results? Annals of Clinical Biochemistry 2012 49 313-322. (doi:10.1258/acb.2011.011248)
30. Hoofnagel AN & Roth MI. Clinical review: Improving the measurement of serum thyroglobulin with mass spectrometry. Journal of Clinical Endocrinology and Metabolism 2013 98 1343-1352. (doi:10.1210/jc.2012-4172)
31. Giovanella L, Suriano S, Ceriani L & Verburg FA. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clinical Nuclear Medicine 2011 36 109-112. (doi:10.1097/RLU.0b013e318203bb84)
32. Giovanella L. False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas. European Journal of Nuclear Medicine and Molecular Imaging 2009 36 326-327. (doi:10.1007/s00259-008-1005-9)
33. Cherk MH, Francis P, Topliss DJ, Bailey M & Kalff V. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal. Clinical Endocrinology 2012 76 734-740. (doi:10.1111/j.1365-2265.2011.04278.x)
34. Giovanella L, Ceriani L, Ghelfo A, Maffioli M & Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clinical Endocrinology 2007 67 547-551. (doi:10.1111/j.1365-2265.2007.02922.x)
35. Tozzoli R, Bizzaro N, Tonutti E, Pradella M, Manoni F, Vilalta D, Bassetti D, Piazza A, Rizzotti P & Italian Society of Laboratory Medicine (SIMeL) Study Group on the Laboratory Diagnosis of Autoimmune Diseases. Immunoassay of anti-thyroid autoantibodies: high analytical variability in second generation methods. Clinical Chemistry and Laboratory Medicine 2002 40 568-573. (doi:10.1515/CCLM.2002.098)
36. Algeciras-Schimnich A, Lasho MA, Ness KM, Cheryk LA & Grebe SK. The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 2011 21 813-814. (doi:10.1089/thy.2011.0158)
37. Spencer C, Petrovic I & Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2011 96 1283-1291. (doi:10.1210/jc.2010-2762)
38. Taylor KP, Parkington D, Bradbury S, Simpson HL, Jefferies SJ & Halsall DJ. Concordance between serum thyroglobulin antibody assays. Annals of Clinical Biochemistry 2011 48 367-369. (doi:10.1258/acb.2011.010248)
39. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas LH, Elisei R, Feldt-Rasmussen U, Rimmele H, Seregni E, Smit JW et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position paper. Thyroid 2013 23 1211-1225. (doi:10.1089/thy.2012.0606)
40. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS & Nicoloff JT. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1998 83 1121-1127. (Pubitemid 28496379)
41. Feldt-Rasmussen U & Rasmussen AK. Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones 2010 9 109-117. (doi:10.14310/horm.2002.1261)
42. Crane MS, Strachan MW, Toft AD & Beckett GJ. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference. Annals of Clinical Biochemistry 2013 50 421-432. (doi:10.1177/0004563213480492)
43. Persoon AC, Links TP, Wilde J, Sluiter WJ, Wolffenbuttel BH & van den Ouweland JM. Thyroglobulin (Tg) recovery testing with quantitative Tg antibody measurement for determining interference in serum Tg assays in differentiated thyroid carcinoma. Clinical Chemistry 2006 52 1196-1199. (doi:10.1373/clinchem. 2005.060103)
44. Verburg FA, Hartmann D, Grelle I, Giovanella L, Buck AK & Reiners C. Relationship between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer. Hormone and Metabolic Research 2013 45 728-735. (doi:10.1055/s-0033-1349890)
45. Giovanella L, Imperiali M, Verburg FA & Ceriani L. Evaluation of the BRAHMS Kryptor(®) thyroglobulin minirecovery test in patients with differentiated thyroid carcinoma. Clinical Chemistry and Laboratory Medicine 2013 51 449-453. (doi:10.1515/cclm-2012-0378)
46. Preissner CM, O'Kane DJ, Singh RJ, Morris JC & Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assay. Journal of Clinical Endocrinology and Metabolism 2003 88 3069-3074. (doi:10.1210/jc.2003-030122)
47. Verburg FA, Wäschle K, Reiners C, Giovanella L & Lentjes EG. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Hormone and Metabolic Research 2010 42 736-739. (doi:10.1055/s-0030-1254132)
48. Giovanella L, Keller F, Ceriani L & Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clinical Chemistry and Laboratory Medicine 2009 47 952-954. (doi:10.1515/CCLM.2009.230)
49. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? Journal of Clinical Endocrinology and Metabolism 2012 97 2748-2753. (doi:10.1210/jc.2012-1123)
50. Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Chougnet CN, Baudin E, Schlumberger M et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. European Journal of Endocrinology 2013 169 689-693. (doi:10.1530/EJE-13-0386)
51. Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C & Luster M. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 276-283. (doi:10.1007/s00259-009-1315-6)
52. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M & Pinchera A. Prediction of disease status by recombinant human TSH stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2001 86 5686-5690. (doi:10.1210/jcem.86.12.8065)
53. Souza do Rosario PW, Ribeiro Borges MA, Fagundes TA, Franco AC & Purisch S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clinical Endocrinology 2005 62 121-125. (doi:10.1111/j.1365-2265.2005.02212.x)
54. Persoon AC, Jager PL, Sluiter WJ, Plukker JT, Wolffenbuttel BH & Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma? PLoS ONE 2007 2 e816. (doi:10.1371/journal.pone.0000816)
55. Giovanella L & Ceriani L. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clinical Chemistry and Laboratory Medicine 2002 40 480-484. (doi:10.1515/CCLM.2002.083)
56. Giovanella L, Ceriani L, Ghelfo A, Keller F, Sacchi A, Maffioli M & Spriano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clinical Chemistry and Laboratory Medicine 2006 44 648-652. (doi:10.1515/CCLM.2006.107)
57. 4<1 ng/ml determined by traditional assays? Clinical Endocrinology 2008 68 338-342. (doi:10.1111/j.1365-2265.2007.03043.x)
58. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A & Pacini F. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. Journal of Endocrinological Investigation 2011 34 e219-e223.
59. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R & Pellegriti G. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. Journal of Clinical Endocrinology and Metabolism 2011 96 1703-1709. (doi:10.1210/jc.2010-2695)
60. Heemstra KA, Lyu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romijn JA & Smit JW. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clinical Endocrinology 2007 66 58-64. (Pubitemid 44952495)
61. Chindris AM, Diehl NN, Crook JE, Fatourechi V & Smallridge RC. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. Journal of Clinical Endocrinology and Metabolism 2012 97 2714-2723. (doi:10.1210/jc.2011- 3017)
62. Rosario PW, dos Santos JB & Calsolari MR. Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study. Hormone and Metabolic Research 2013 45 911-914. (doi:10.1055/s-0033-1347264)
63. Spencer C, Fatemi S, Singer P, Nicoloff J & Lopresti J. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010 20 587-595. (doi:10.1089/thy.2009.0338)
64. Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L & Verburg FA. Unstimulated high-sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2014 99 440-447. (doi:10.1210/jc.2013-3156)
65. Nakabashi CCD, Kasamatsu TS, Crispim F, Yamazaki CA, Camacho CP, Andreoni DM, Padovani RP, Ikejiri ES, Mamone MC, Aldighieri FC et al. Basal serum thyroglobulin measured by a second-generation assay is equivalent to stimulated thyroglobulin in identifying metastases in patients with differentiated thyroid cancer with low or intermediate risk of recurrence. European Thyroid Journal 2014 3 43-50. (doi:10.1159/000360077)
66. Giovanella L, Ceriani L & Maffioli M. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head & Neck 2010 32 568-571. (doi:10.1002/hed.21214)
67. Feldt-Rasmussen U, Bech K, Date J, Hyltoft Pedersen P, Johansen K & Nistrup Madsen S. Thyroid stimulating antibodies, thyroglobulin antibodies and serum proteins during treatment of Graves' disease with radioiodine or propylthiouracil. Allergy 1982 37 161-167. (doi:10.1111/j.1398-9995.1982. tb01892.x)
68. Padovani RP, Robenshtok E, Brokhin M & Tuttle RM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 2012 22 778-783. (doi:10.1089/thy.2011. 0522)
69. Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T & Russ G. European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. European Thyroid Journal 2013 2 147-159. (doi:10.1159/000354537)
70. Valle LA, Gorodeski Baskin RL, Porter K, Sipos JA, Khawaja R, Ringel MD & Kloos RT. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. Thyroid 2013 23 185-193. (doi:10.1089/thy.2012.0327)
71. Ross HA, Netea-Maier RT, Schakenraad E, Bravenboer B, Hermus AR & Sweep FC. Assay bias may invalidate decision limits and affect comparability of serum thyroglobulin assay methods: an approach to reduce interpretation differences. Clinica Chimica Acta 2008 394 104-109. (doi:10.1016/j.cca.2008.04. 020)